Janus Henderson Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $202M | Buy |
1,009,891
+14,491
| +1% | +$2.87M | 0.1% | 191 |
|
|
2025
Q4 | $188M | Sell |
995,400
-46,978
| -5% | -$9.03M | 0.08% | 201 |
|
|
2025
Q3 | $185M | Sell |
1,042,378
-18,356
| -2% | -$2.73M | 0.08% | 195 |
|
|
2025
Q2 | $121M | Buy |
1,060,734
+33,185
| +3% | +$3.55M | 0.06% | 241 |
|
|
2025
Q1 | $111M | Buy |
1,027,549
+12,526
| +1% | +$1.42M | 0.06% | 252 |
|
|
2024
Q4 | $109M | Buy |
1,015,023
+5,929
| +0.6% | +$670K | 0.06% | 266 |
|
|
2024
Q3 | $101M | Buy |
1,009,094
+361
| +0% | +$36.3K | 0.05% | 278 |
|
|
2024
Q2 | $85M | Buy |
1,008,733
+256
| +0% | +$20.4K | 0.05% | 284 |
|
|
2024
Q1 | $73.7M | Sell |
1,008,477
-334,677
| -25% | -$24.7M | 0.04% | 315 |
|
|
2023
Q4 | $95.9M | Buy |
1,343,154
+1,281
| +0.1% | +$75.6K | 0.06% | 258 |
|
|
2023
Q3 | $80.4M | Sell |
1,341,873
-2,682
| -0.2% | -$177K | 0.05% | 269 |
|
|
2023
Q2 | $96.9M | Buy |
1,344,555
+84,670
| +7% | +$6.35M | 0.06% | 259 |
|
|
2023
Q1 | $92.7M | Buy |
1,259,885
+4,612
| +0.4% | +$328K | 0.06% | 263 |
|
|
2022
Q4 | $83.9M | Sell |
1,255,273
-2,791,767
| -69% | -$182M | 0.06% | 269 |
|
|
2022
Q3 | $217M | Buy |
4,047,040
+1,819,691
| +82% | +$107M | 0.08% | 225 |
|
|
2022
Q2 | $124M | Buy |
2,227,349
+675
| +0% | +$38.3K | 0.09% | 225 |
|
|
2022
Q1 | $156M | Sell |
2,226,674
-83,385
| -4% | -$6.05M | 0.08% | 241 |
|
|
2021
Q4 | $223M | Sell |
2,310,059
-34,970
| -1% | -$3.23M | 0.09% | 217 |
|
|
2021
Q3 | $204M | Buy |
2,345,029
+29,943
| +1% | +$2.32M | 0.09% | 232 |
|
|
2021
Q2 | $189M | Buy |
2,315,086
+298,837
| +15% | +$24.9M | 0.08% | 246 |
|
|
2021
Q1 | $192M | Sell |
2,016,249
-568,379
| -22% | -$53.7M | 0.09% | 228 |
|
|
2020
Q4 | $160M | Buy |
2,584,628
+10,144
| +0.4% | +$578K | 0.07% | 268 |
|
|
2020
Q3 | $153M | Buy |
2,574,484
+1,711
| +0.1% | +$117K | 0.08% | 245 |
|
|
2020
Q2 | $180M | Buy |
2,572,773
+21,467
| +0.8% | +$1.36M | 0.1% | 213 |
|
|
2020
Q1 | $116M | Sell |
2,551,306
-362,105
| -12% | -$20.5M | 0.08% | 252 |
|
|
2019
Q4 | $190M | Buy |
2,913,411
+403,078
| +16% | +$26.9M | 0.1% | 225 |
|
|
2019
Q3 | $156M | Buy |
2,510,333
+37,433
| +2% | +$2.35M | 0.08% | 261 |
|
|
2019
Q2 | $176M | Buy |
2,472,900
+252,639
| +11% | +$18.6M | 0.1% | 243 |
|
|
2019
Q1 | $174M | Buy |
2,220,261
+635,054
| +40% | +$48.1M | 0.1% | 244 |
|
|
2018
Q4 | $134M | Buy |
1,585,207
+142,368
| +10% | +$15.2M | 0.09% | 278 |
|
|
2018
Q3 | $247M | Sell |
1,442,839
-43,304
| -3% | -$6.53M | 0.13% | 195 |
|
|
2018
Q2 | $192M | Buy |
1,486,143
+88,149
| +6% | +$9.84M | 0.11% | 237 |
|
|
2018
Q1 | $144M | Sell |
1,397,994
-67,765
| -5% | -$6.7M | 0.08% | 277 |
|
|
2017
Q4 | $125M | Buy |
1,465,759
+255,988
| +21% | +$22.2M | 0.08% | 314 |
|
|
2017
Q3 | $103M | Buy |
1,209,771
+255,199
| +27% | +$20.2M | 0.07% | 354 |
|
|
2017
Q2 | $72.3M | Buy |
+954,572
| New | +$66.8M | 0.05% | 427 |
|
Other funds holding LGND
NAMI
CC
Janus Henderson Group's LGND Position: Q1 2026 in Review
Janus Henderson Group increased its Ligand Pharmaceuticals (LGND) stake by 1.5% in Q1 2026, buying an estimated $2.87M and bringing the position to 1,009,891 shares worth $202M. The position accounts for 0.1% of the portfolio, ranked #191.
Janus Henderson Group first reported a position in LGND in Q2 2017 and has held it in 36 quarters since. The position peaked at $247M in Q3 2018. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Janus Henderson Group held 1,009,891 shares of Ligand Pharmaceuticals worth $202M as of Q1 2026.
- Janus Henderson Group bought 14,491 Ligand Pharmaceuticals shares in Q1 2026, an estimated $2.87M.
- Ligand Pharmaceuticals made up 0.1% of Janus Henderson Group's portfolio in Q1 2026, its #191 holding.
- Janus Henderson Group first reported a position in Ligand Pharmaceuticals in Q2 2017 and has held it in 36 quarters since.
- Janus Henderson Group's Ligand Pharmaceuticals position peaked at $247M in Q3 2018.
- 358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.